Clinical trial
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
NCT02065466 · University of Arizona, Other · Withdrawn
Key facts
| NCT number | NCT02065466 |
|---|---|
| Title | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases |
| Official title | A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases |
| Lead sponsor | University of Arizona, Other |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma, Brain Metastases |
| Intervention type | Drug |
| Interventions | nab-paclitaxel, Temozolomide, Bevacizumab |
| Enrollment | 0 |
| Start date | Jul 1, 2014 |
| Primary completion | Feb 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Feb 19, 2014 |
| Last update posted | Apr 21, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: